Sponsor Dossier
Hameln Pharma
Sponsor Dossier for Hameln Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ALFENTANIL-HAMELN
- Brand: CYCLIZINE-HAMELN
- Brand: DOBUTAMINE-HAMELN
- Brand: EPHEDRINE-HAMELN
- Brand: FENTANYL-HAMELN
- Brand: HYDROMORPHONE-HAMELN
- Brand: HYDROMORPHONE-HAMELN-HP
- Brand: OXYCODONE-HAMELN
About
Hameln Pharma is an Australian Private Company with ABN 69638348580, registered in Victoria. The entity is active and registered for GST from 8 January 2020.
Portfolio
Hameln Pharma has 9 brands on the ARTG, of which 7 are indexable and 7 carry a Product Information document. 2 brands are PBS-listed, 0 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include ALFENTANIL-HAMELN, CYCLIZINE-HAMELN, DOBUTAMINE-HAMELN, EPHEDRINE-HAMELN, FENTANYL-HAMELN, HYDROMORPHONE-HAMELN, HYDROMORPHONE-HAMELN-HP, OXYCODONE-HAMELN, ROCURONIUM-HAMELN.
Therapeutic focus
— Pain Management: 5 brands — Cardiology: 2 brands — Gastroenterology: 1 brand — Other: 1 brand
PBS footprint
2 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.